Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10666592 | 0.79 | CYP3A4 (0.50) | CYP3A4BLMSCN9ASCN5AMEN1 | |
| SCHEMBL3220141 | 0.74 | PDE2A (0.48) | PDE2A | |
| SCHEMBL7161983 | 0.72 | — | — | |
| SCHEMBL10664400 | 0.72 | NUDT1 (0.40) | CYP3A4BLMPIK3CBMEN1KMT2A | |
| SCHEMBL11497510 | 0.72 | CYP3A4 (0.46) | CYP3A4BLMSCN9ASCN5AMEN1 | |
| SCHEMBL18247929 | 0.72 | PDE2A (0.51) | PDE2A | |
| SCHEMBL466114 | 0.72 | — | — | |
| SCHEMBL8723531 | 0.68 | — | — | |
| SCHEMBL6777122 | 0.68 | CYP3A4 (0.55) | CYP3A4BLMSCN9ASCN5AMEN1 | |
| SCHEMBL12660894 | 0.68 | CYP3A4 (0.55) | CYP3A4BLMSCN9ASCN5AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812041-B2 | Heterocyclic NF-κB inhibitors | 4SC AG (DE) | 2010-10-12 | — | — | US | disclosed |
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | 4SC AG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | 4SC AG (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | 4 SC AG (DE) | 2006-03-30 | — | — | US | disclosed |
| US-4739053-A | CHARGE CARRIER-TRANSPORTING COMPOUNDS; ELECTROGRAPHY | BASF AKTIENGESELLSCHAFT (DE) | 1988-04-19 | — | — | US | disclosed |
| EP-0185346-A2 | Imidazo derivatives, their preparation and medicaments containing these compounds | Dr. Karl Thomae GmbH (DE) | 1986-06-25 | — | — | EP | disclosed |
| US-4302586-A | FLUORESCENT WHITENERS | CIBA-GEIGY CORPORATION (US) | 1981-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048583-A1 | Novel Heterocyclic NF-kB Inhibitors | NFKBIA, NFKB2, NFRKB | CYP3A4 2254/4885BLM 2971/4885PIK3CB 2710/4885 |
| US-20080261971-A1 | Novel Heterocyclic Nf-Kb Inhibitors | NFKBIA, NFKB2, NFRKB | CYP3A4 2150/4885BLM 2919/4885PIK3CB 2751/4885 |
| US-20060069102-A1 | Novel heterocyclic NF-kB inhibitors | NFKBIA, NFKB2, NFRKB | CYP3A4 2199/4885BLM 3033/4885PIK3CB 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.